FDA Accepts sNDA for Tapinarof Cream 1% for Treatment of Atopic Dermatitis
Drug Topics
APRIL 29, 2024
The ADORING 3 phase 3 development program is currently studying the novel, aryl hydrocarbon receptor agonist as a once-daily, cosmetically elegant, and steroid-free topical cream for adults and children with atopic dermatitis.
Let's personalize your content